礼来公司首席财务官表示，一旦Orforglipron获得美国食品药品监督管理局（FDA）的批准，预计仅需一周左右时间便能完成向客户及患者的药品发运工作。这一高效的分发流程凸显了公司对加速创新疗法可及性的承诺。
礼来公司首席财务官表示，一旦Orforglipron获得美国食品药品监督管理局（FDA）的批准，预计仅需一周左右时间便能完成向客户及患者的药品发运工作。这一高效的分发流程凸显了公司对加速创新疗法可及性的承诺。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.